 Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapy Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapy 